Please assess the completion status of the following clinical trial:

Trial Title: Aspirin for Treatment of Multiple Sclerosis-Related Fatigue

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~* Confirmed relapsing-remitting or secondary progressive multiple sclerosis,~* Ambulatory for distance of at least 100 meters without gait assistance,~* Persistent fatigue for at least 8 weeks that is not attributable to causes other than MS, and~* Will be able to complete questionnaires and cognitive testing.~Exclusion criteria:~1. Other evident causes for fatigue:~   * Untreated depression or screening Center for Epidemiologic Studies Depression (CES-D) scale greater than 28~  * Significant cognitive impairment (Baseline Short Test of Mental Status score of less than 29/38)~  * Narcolepsy, uncontrolled sleep apnea, or other primary sleep disorder judged to be likely a major contributor to fatigue~  * Screening Epsworth Sleepiness Scale score greater than 15~  * Uncontrolled hypothyroidism or anemia~  * Other medical illness judged by the investigator to affect the participant's fatigue complaints including current viral, bacterial, mycobacterial, or fungal infection~2. MS Disease Activity and Treatment:~   * Clinical exacerbations within 2 weeks prior to screening visit~  * Corticosteroid use within 4 weeks prior to screening visit~  * Beta-interferon, glatiramer acetate, immunosuppressant drugs (mitoxantrone, azathioprine, etc.) are permitted if a stable dose has been used for greater than or equal to 4 weeks and there is no temporal association of drug administration with perceived fatigue; elective on-study dose/regimen changes are not permitted~3. Current or Recent Fatigue Therapy and Other Medications:~   * Use of more than two doses of ASA (aspirin) greater than 81 mg/d within 2 weeks of screening visit~  * Use of MS fatigue medications within 2 weeks of screening visit (including amantadine or Central Nervous System stimulants such as modafinil, methylphenidate, and pemoline)~  * Symptomatic medications (antidepressants, anti-spasticity agents, non-narcotic analgesics) are permitted if a stable dose has been used for \>4 weeks prior to screening for antidepressants and \>2 weeks prior to screening for other symptomatic therapies and there is no temporal association of drug administration with perceived fatigue; elective on-study dose changes are not permitted.~  * Current use of acetazolamide, antiplatelet agents or anticoagulants, COX-2 inhibitors, methotrexate, oral hypoglycemic medications~4. Medical Contraindications to ASA use:~   * Allergy to ASA or Non-Steroidal Anti-Inflammatory drugs~  * Syndrome of asthma, rhinitis and nasal polyps~  * History of confirmed peptic ulcer or gastrointestinal or severe gynecological bleeding~5. General Health Concerns:~   * Significant uncontrolled disease of cardiovascular, pulmonary, hepatic, renal, endocrine, rheumatological, neurological, gynecological, or gastrointestinal systems~  * Pregnancy or unwillingness to utilize contraception~  * History of alcohol or drug abuse within 6 months of screening or current alcohol intake \>3 drinks/day~6. Laboratory Exclusions (available values obtained within 8 weeks prior to screening visit are acceptable for all except the pregnancy test)~   * Positive pregnancy test~  * Hemoglobin less than 11.0 g/dL (women) or 13.0 g/dL (men)~  * Platelet count \< 120, 000/μL~  * Serum creatinine level \> 1.4 mg/dL (women) or 1.6 mg/dL (men)~  * Aspartate aminotransferase (AST/SGOT) or alanine aminotransferase (ALT/SGPT) level greater than 2.5 times the upper limit of normal

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- High Dose Aspirin (Type: ACTIVE_COMPARATOR): High Dose Aspirin; 1300 milligrams of aspirin per day, taken by mouth as two tablets, twice per day for 8 weeks
- Low Dose Aspirin (Type: ACTIVE_COMPARATOR): Low Dose Aspirin; 162 milligrams of aspirin per day (the equivalent of 2 baby aspirin tablets) taken by mouth as two tablets, twice a day in the morning and at noon for 8 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo tablets, matching the active aspirin tablets in appearance, taken by mouth twice per day for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues